PPARγ、M-CSF、CA125和HE4在卵巢浆液性上皮肿瘤中的表达及其临床意义

发布时间：2018-04-29 01:40

本文选题：卵巢浆液性上皮肿瘤 + PPARγ　；参考：《苏州大学》2014年硕士论文

【摘要】：目的：分别检测卵巢浆液性囊腺瘤、交界性囊腺瘤和囊腺癌中PPARγ、M-CSF、CAl25和HE4的表达，初步探讨PPARγ、M-CSF、CAl25和HE4在卵巢浆液性囊腺癌中的表达与其分化程度、病理分期及有无淋巴结转移的关系。方法：选取卵巢浆液性上皮肿瘤70例，其中囊腺瘤20例、交界性囊腺瘤10例、囊腺癌40例。以已知阳性的乳腺癌切片作为阳性对照，以PBS替代一抗作为阴性对照。采用免疫组化法对选取的70例卵巢浆液性上皮肿瘤进行PPARγ、M-CSF、CAl25和HE4检测，并分析其病理意义。结果： 1. PPARγ在卵巢浆液性囊腺瘤组中的阳性表达率(30.00%)低于交界性囊腺瘤(60.00%)和囊腺癌(72.50%)(P0.05)；M-CSF在囊腺瘤组中的阳性表达率(10.00%)显著低于交界性囊腺瘤(60.00%)和囊腺癌(70.00%)(P0.05)；CAl25在卵巢囊腺瘤组中的阳性表达率(20.00%)低于交界性囊腺瘤(60.00%)和囊腺癌(65.00%)(P0.05)；HE4在囊腺瘤组中的阳性表达率(0.00%)显著低于交界性囊腺瘤(70.00%)和囊腺癌(80.00%)(P0.05)。 2. PPARγ、M-CSF、CAl25和HE4在卵巢浆液性囊腺癌中的表达皆与其分化程度呈负相关关系，与其临床病理分期和有无淋巴转移呈正相关关系。 3.与单项检测相比，，PPARγ、M-CSF、CA125和HE4四者联合检测可以提高卵巢浆液性囊腺癌的诊断率。结论： 1.PPARγ、M-CSF、CA125和HE4在卵巢浆液性上皮肿瘤中的表达与其病变程度、分化程度、临床分期、有无淋巴转移有一定的相关性。 2.PPARγ、M-CSF、CA125和HE4四者联合检测可以提高卵巢浆液性囊腺癌的诊断率，故有可能成为检测卵巢浆液性囊腺癌的良好指标。
[Abstract]:Objective: to detect the expression of PPAR 纬 -M-CSFFCAl25 and HE4 in serous cystadenoma, borderline cystadenoma and cystadenocarcinoma, and to explore the relationship between the expression of PPAR 纬 -M-CSFCal CAl25 and HE4 in ovarian serous cystadenocarcinoma and its differentiation, pathological stage and lymph node metastasis. Methods: 70 cases of ovarian serous epithelial tumors were selected, including 20 cases of cystadenoma, 10 cases of borderline cystadenoma and 40 cases of cystadenocarcinoma. Breast cancer sections with known positive results were used as positive controls and PBS as negative controls instead of first antibody. 70 cases of ovarian serous epithelial tumors were examined by immunohistochemical method for PPAR 纬 -M-CSFU CAl25 and HE4, and their pathological significance was analyzed. Results: 1. The positive expression rate of PPAR 纬 in ovarian serous cystadenoma group was significantly lower than that in borderline cystadenoma group (P 0.05 M CSF) and cystadenocarcinoma (72.50% P 0.05 M CSF) in ovarian cystadenoma group. The positive expression rate of PPAR 纬 in ovarian cystadenoma group was significantly lower than that in borderline cystadenoma group. The positive expression rate of cystadenocarcinoma and cystadenocarcinoma in cystadenoma group was significantly lower than that in borderline cystadenoma group (P 0.05) and cystadenocarcinoma group (P 0.05), and the positive expression rate of cystadenocarcinoma was significantly lower than that of borderline cystadenoma and cystadenocarcinoma (P 0.05). The positive expression rate of cystadenoma and cystadenocarcinoma was significantly lower than that of borderline cystadenoma and cystadenocarcinoma. 2. The expression of PPAR 纬 -M-CSFU CAl25 and HE4 in ovarian serous cystadenocarcinoma was negatively correlated with its differentiation, and positively correlated with its clinicopathologic stage and lymphatic metastasis. 3. Compared with single detection, combined detection of PPAR- 纬 -M-CSFCA125 and HE4 could improve the diagnosis rate of ovarian serous cystadenocarcinoma. Conclusion: The expression of 1.PPAR 纬 -M-CSFCF-CA125 and HE4 in ovarian serous epithelial tumors was correlated with the degree of lesion, differentiation, clinical stage and lymphatic metastasis. The combined detection of 2.PPAR 纬 M-CSF CA125 and HE4 can improve the diagnostic rate of ovarian serous cystadenocarcinoma, so it may be a good index for detecting ovarian serous cystadenocarcinoma.
【学位授予单位】：苏州大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.31

【参考文献】